Ossium Health Launches HOPE Program to Give All Patients Hope for a Cure
2024年5月11日 - 3:32AM
ビジネスワイヤ(英語)
Ossium Health, an innovative bioengineering company that
established a first-of-its-kind bone marrow bank, announced today
the launch of a new program that further expands patient access to
Ossium’s bone marrow. Through the HOPE (HPC Offered for
PRESERVE Expansion) Program, patients that need an
allogeneic bone marrow transplant but are ineligible to participate
in Ossium’s active clinical study (PRESERVE I) have a new
opportunity to receive bone marrow from Ossium’s bank.
The goal of Ossium’s PRESERVE trials is to establish organ donor
bone marrow as a new source of stem cells for hematologic
reconstitution and unlock access to stem cell transplants for the
thousands of patients who search unsuccessfully for a donor each
year. The company recently initiated the PRESERVE I clinical study
and is currently enrolling patients at five transplant centers
across the United States. Through PRESERVE I, 12 patients with
acute leukemias will receive a transplant with bone marrow from
Ossium’s bank, generating the safety and efficacy data required to
initiate a long-term phase 2 study (PRESERVE II).
Ossium launched the HOPE Program after recognizing the sheer
volume of patients that need a bone marrow transplant but are
unable to participate in the PRESERVE I study due to its
eligibility criteria or the patient’s geography. For example,
patients that have a non-malignant blood disorder or that live
outside the US may not be able to participate in the PRESERVE I
study but could be eligible to receive a transplant through the
HOPE Program.
“Thousands of patients in the US and tens of thousands abroad
desperately need a bone marrow transplant but can’t find a donor,”
said Kevin Caldwell, Ossium’s CEO, Co-Founder & President.
“While the PRESERVE clinical program will provide the data
necessary to enter global registries and improve bone marrow
accessibility long-term, these patients can’t wait for us to
complete our clinical study. The HOPE Program is intended to fill
that gap.”
Through the HOPE Program, patients across the globe can receive
bone marrow from Ossium’s bank free of charge. Since Ossium’s bone
marrow is cryopreserved and available on-demand, physicians can
order it from Ossium and receive the product within days, allowing
unrelated donor transplants to be performed at unprecedented
speeds.
To learn more about the HOPE Program or request to participate,
visit https://ossiumhealth.com/hope.
About Ossium Health
Ossium Health is a bioengineering company that leverages its
proprietary organ donor bone marrow banking platform to develop
stem cell therapies for patients with life-threatening blood and
immune diseases. Founded in 2016, the company is led by Kevin
Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief
Science Officer, Co-Founder & EVP. Ossium Health’s
manufacturing facility is registered with the FDA and its
laboratory is certified under the Clinical Laboratory Improvement
Amendments (CLIA).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240510961254/en/
Jane Griffin Ossium Health, Inc. 415-513-5535
press@ossiumhealth.com